Stock events for HeartSciences, Inc. (HSCS)
HeartSciences' stock price decreased by 13.97% between January 6, 2025, and January 2, 2026. The stock decreased by 1.9% to $3.03. The fiscal second-quarter 2026 financial results showed no meaningful revenue, leading to a 6.5% stock decline. The company announced an FDA 510(k) submission for its MyoVista wavECG device and the commercial release of MyoVista Insights version 1.1 on December 15, 2025 and December 11, 2025 respectively. The fiscal first-quarter 2026 financial results also showed no meaningful revenue.
Demand Seasonality affecting HeartSciences, Inc.’s stock price
HeartSciences Inc. exhibits some demand seasonality for its stock. May has the highest probability of a positive return at 66.67%, while March has the lowest at 0.00%. January shows a 25.00% probability of positive returns.
Overview of HeartSciences, Inc.’s business
HeartSciences, Inc. is a medical technology company using AI to improve ECG utility for early heart disease detection. They offer AI-ECG solutions, the MyoVista wavECG device, and the MyoVista Insights cloud platform. Their goal is to make ECGs a more valuable cardiac screening tool. The company was formerly known as Heart Test Laboratories, Inc. and changed its name in October 2024.
HSCS’s Geographic footprint
HeartSciences is headquartered in Southlake, Texas, and conducts R&D in the United States. They have 41 patents across the United States, China, Brazil, Canada, India, South Korea, Mexico, and key European markets. The technology has regulatory clearance in the United States and the European Union.
HSCS Corporate Image Assessment
HeartSciences' brand reputation has been influenced by its name change in October 2024. Analyst sentiment is mixed, with one "Strong Buy" rating and a $9.20 price target, but the consensus is "Hold." The company faced a Nasdaq delisting notice in May 2025 but was granted an extension to regain compliance in January 2025, and subsequently received a decision from the panel granting its request for continued listing.
Ownership
HeartSciences, Inc. is primarily owned by retail investors (91.38%), followed by institutional shareholders (5.51%) and HeartSciences insiders (3.11%). Major institutional owners include DRW Securities LLC, TFB Advisors LLC, Astoria Strategic Wealth, Inc., Vanguard Group Inc, Geode Capital Management, Llc and Advisory Services Network, LLC. The largest individual shareholder is Andrew Simpson, owning 2.34% of the company.
Ask Our Expert AI Analyst
Price Chart
$3.50
